2023
DOI: 10.1016/s2213-8587(23)00116-x
|View full text |Cite|
|
Sign up to set email alerts
|

Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
4
1
4

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 29 publications
(9 citation statements)
references
References 145 publications
0
4
1
4
Order By: Relevance
“…Moreover, substantial evidence has shown that switching to IDeg from different basal insulins (both in patients with T1D and T2D) was cost effective and was associated with improved glycaemic control, higher time in range, less glycaemic variability in difficult to control populations, less basal and total insulin doses and lower risk of hypoglycaemia (overall and nocturnal), making IDeg a valuable tool in our therapeutic armamentarium in pregestational diabetes [ 39 44 ]. However, in women with pregestational diabetes who experience hyperglycaemic spikes during the early morning hours (mainly patients with T1D) and/or experience basal rate profiles with significant intraday variability as pregnancy progresses, IDeg may not be the proper therapeutic approach due to its flat and stable blood glucose-lowering effect; continuous subcutaneous insulin infusion should be the preferred therapeutic approach in this setting [ 45 47 ].…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, substantial evidence has shown that switching to IDeg from different basal insulins (both in patients with T1D and T2D) was cost effective and was associated with improved glycaemic control, higher time in range, less glycaemic variability in difficult to control populations, less basal and total insulin doses and lower risk of hypoglycaemia (overall and nocturnal), making IDeg a valuable tool in our therapeutic armamentarium in pregestational diabetes [ 39 44 ]. However, in women with pregestational diabetes who experience hyperglycaemic spikes during the early morning hours (mainly patients with T1D) and/or experience basal rate profiles with significant intraday variability as pregnancy progresses, IDeg may not be the proper therapeutic approach due to its flat and stable blood glucose-lowering effect; continuous subcutaneous insulin infusion should be the preferred therapeutic approach in this setting [ 45 47 ].…”
Section: Discussionmentioning
confidence: 99%
“…Серед усіх ендокринних захворювань у популяції одне з провідних місць займає цукровий діабет (ЦД) -група метаболічних захворювань, що проявляються гіперглікемією. Ця патологія є однією з найпоширеніших і трапляється в 0,5% жінок репродуктивного віку до вагітності (прегестаційний ЦД) [1,2].…”
unclassified
“…ЦД становить ризик для матері у зв'язку з високою можливістю виникнення кетоацидозу, невиношування вагітності, запальних захворювань урогенітального тракту (гострий пієлонефрит, кольпіт), багатоводдя, інфікування, гестозу, слабкості пологової діяльності тощо [2]. Ризиками для плода при ЦД матері є діабетична фетопатія, вади розвитку (серця, хребта, спинного мозку, шлунково-кишкового тракту), макросомія, травматизм, респіраторний дистрес-синдром, гіпоглікемія, інфікування [3,6].…”
unclassified
See 2 more Smart Citations